Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 194

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey

Deschildre, Antoine, Marguet, Christophe, Salleron, Julia, Pin, Isabelle, Rittié, Jean-Luc, Derelle, Jocelyne, Taam, Rola Abou, Fayon, Mickael, Brouard, Jacques, Dubus, Jean Christophe, Siret, Daniel, Weiss, Laurence, Pouessel, Guillaume, Beghin, Laurent, Just, Jocelyne · 2013 · European Respiratory Journal

Abstract

Omalizumab has been shown to reduce exacerbation rates in moderate to severe allergic asthma. Our aim was to evaluate omalizumab efficacy and safety in a real-life setting in severe asthmatic children. 104 children (aged 6–18 years), followed up in paediatric pulmonary tertiary care centres, were included at the beginning of omalizumab treatment. Asthma control levels, exacerbations, inhaled corticosteroid dose, lung function and adverse events were evaluated over 1 year. Children were characterised by allergic sensitisation to three or more allergens (66%), high IgE levels (mean 1125 kU·L−1), high rate of exacerbations (4.4 per year) and healthcare use during the previous year, and high inhaled corticosteroid dose (mean 703 μg equivalent fluticasone per day). Asthma control levels defined as good, partial or poor, improved from 0%, 18% and 82% at entry to 53%, 30% and 17% at week 20, and to 67%, 25% and 8% at week 52, respectively (p<0.0001). Exacerbation and hospitalisation rates dropped by 72% and 88.5%, respectively. At 12 months, forced expiratory volume in 1 s improved by 4.9% (p=0.023), and inhaled corticosteroid dose decreased by 30% (p<0.001). Six patients stopped omalizumab for related significant adverse events. Omalizumab improved asthma control in children with severe allergic asthma and was generally well tolerated. The observed benefit was greater than that reported in clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/09031936.00149812

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 194

Metadata

Authors
Deschildre, A., Marguet, C., Salleron, J., Pin, I., Rittié, J.-L., Derelle, J., Taam, R. A., Fayon, M., Brouard, J., Dubus, J. C., Siret, D., Weiss, L., Pouessel, G., Beghin, L., & Just, J.
Venue
European Respiratory Journal
Published
2013-03-21
Volume
42
Issue
5
Pages
1224-1233
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W2164548578
Cited by
194
References
2
FWCI
8.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. https://app.cochat.ai/papers/10.1183/09031936.00149812
The paper
Deschildre, A., Marguet, C., Salleron, J., Pin, I., Rittié, J.-L., Derelle, J., Taam, R. A., Fayon, M., Brouard, J., Dubus, J. C., Siret, D., Weiss, L., Pouessel, G., Beghin, L., & Just, J. (2013). Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. European Respiratory Journal. https://doi.org/10.1183/09031936.00149812

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.